The monoclonal antibody is the first non-factor, once-weekly treatment approved in the United States for hemophilia B.

The FDA approved Pfizer’s Hympavzi (marstacimab-hncq) to prevent or reduce the frequency of bleeding episodes in patients age ...

Pfizer Inc. (PFE) announced Friday that the U.S. Food and Drug Administration has approved HYMPAVZI (marstacimab-hncq) for routine ...

Hemophilia A and hemophilia B are genetic bleeding disorders caused by a dysfunction or deficiency of coagulation factor VIII ...

The FDA approved marstacimab (Hympavzi) for routine prophylaxis to prevent or reduce bleeding episodes in adults and ...

Pfizer Inc. has won regulatory approval for its hympavzi drug as a treatment for hemophilia A or B without inhibitors - making it the first antitissue-factor pathway inhibitor to be allowed for the ...

Patients suffering from hemophilia received a "meaningful" advancement on Friday when federal regulators approved the first ...

The summary covers major health news, including six transplant patients in Brazil contracting HIV from infected organs, ...

Recent health developments include HIV infections from organ transplants in Brazil, Sanofi's potential sale of a stake in its ...

NEW YORK, NY, USA I October 11, 2024 I Pfizer Inc. (NYSE: PFE)announced today that the U.S. Food and Drug Administration (FDA) has approved HYMPAVZI™ ...

Get the latest updates on the stock market, including the S&P 500 hitting a new high and top trending stocks like Cloudflare, ...